Clik here to view.
Study: Most commonly-prescribed diabetes drug linked to lowest rate of...
Patients who take the most-commonly prescribed diabetes medication, metformin, are the least likely to adhere to a prescribed regimen, according to a study published in the journal Diabetes, Obesity...
View ArticleClik here to view.
Bigfoot Biomedical raises $37m in Series B
Bigfoot Biomedical said today that it has raised $37 million in the first tranche of a Series B round, co-led by new investor Janus Henderson Investors and the company’s largest existing investor,...
View ArticleClik here to view.
Sensorion, Cochlear collab to study combo therapies for patients with...
Sensorion, a biotech working on therapies for inner ear diseases, said today that it inked a deal with Cochlear Ltd (ASX:COH) to study combination therapies for patients with cochlear implants....
View ArticleClik here to view.
Report: Protest over Teva layoffs shuts down Israel’s airport, banks
Israel’s public-sector labor union staged a strike yesterday to protest Teva Pharmaceuticals‘ (NYSE:TEVA) move to cut more than 25% of its global workforce in an effort to restructure the company. Teva...
View ArticleClik here to view.
Aerie’s glaucoma eye drops win early FDA nod
Aerie Pharmaceuticals (NSDQ:AERI) won an early FDA nod for its glaucoma drug, Rhopressa. The agency was slated to make a decision about the company’s eye drops in February. The win for Aerie came after...
View ArticleClik here to view.
5 tips for developing a connected drug-delivery device
Now more than ever, people are carrying their computers at their fingertips and managing nearly every aspect of their lives online – including their health. Meanwhile, the medtech and pharmaceutical...
View ArticleClik here to view.
IntelGenx to reclaim global rights to oral thin-film migraine treatment
IntelGenx (CVE:IGX) is slated to regain exclusive global rights to develop and sell its Rizaport oral thin-film acute migraine treatment in January, according to a report from BioTuesdays. The...
View ArticleClik here to view.
Study: Novocure’s Optune, drug combo adds months to the lives of GBM patients
Novocure (NSDQ:NVCR) touted today the final analysis of a pivotal Phase III trial that evaluated Optune combined with temozolomide in newly-diagnosed glioblastoma patients. The analysis, published...
View ArticleClik here to view.
Bristol-Myers Squibb taps Taris’ drug-release tech for bladder cancer trial
Bristol-Myers Squibb (NYSE:BMY) and Taris Biomedical have inked a deal to combine Taris’ investigational GemRIS drug-releasing tech with the pharma company’s PD-1 immune checkpoint inhibitor, Opdivo,...
View ArticleClik here to view.
7 medical devices combating the opioid crisis
[Image from unsplash.com]Opioid-related deaths have become an epidemic in the U.S., garnering attention from the White House, the FDA and many other governmental bodies. From 2000 to 2014, nearly half...
View ArticleClik here to view.
Mass Innovation Labs expands to give startups a better way to do research
At the 124,000-square foot Cambridge headquarters of Mass Innovation Labs, co-founder & CEO Amrit Chaudhuri points to a cluster of tables and identifies them one by one: This startup went public...
View ArticleClik here to view.
Eyenovia looks to $35m IPO for ocular drug-delivery tech
Eyenovia is looking to raise up to $35 million in an initial public offering, according to recent filings. The company plans to use the funds to support trials of its device, which is designed to...
View ArticleClik here to view.
TherapeuticsMD shares tumble after FDA pushes NDA decision to mid ’18
TherapeuticsMD (NSDQ:TXMD) shares fell -7% yesterday after the company announced that the FDA accepted its resubmitted application for TX-004HR, an investigational, applicator-free estradiol vaginal...
View ArticleClik here to view.
BioCorp’s smart cap wins CE Mark for insulin pen
Biocorp (PAR:ALCOR) said today that its smart cap, Easylog, won CE Mark clearance for use with insulin delivery devices. The company’s device turns traditional pen injectors into connected devices,...
View ArticleClik here to view.
Aura Biosciences raises $30m for nanoparticle cancer treatment
Aura Biosciences has closed a $30 million Series C round with funding from new investors like Arix Bioscience and Lundbeckfonden Ventures, as well as existing investors, including the estate of...
View ArticleClik here to view.
Illinois AG sues Baxter for polluting lake
Illinois attorney general Lisa Madigan hit Baxter Healthcare (NYSE:BAX) with a lawsuit yesterday, alleging that the company’s R&D facility dumped contaminated wastewater into a tributary that feeds...
View ArticleClik here to view.
FDA rejects Santen’s intravitreal uveitis therapy
Shares in Santen Pharmaceutical (OTC:SNPHY) fell -3% today after the company’s U.S. subsidiary said that the FDA rejected the application for its intravitreal sirolimus therapy The company is...
View ArticleClik here to view.
United Therapeutics dishes out $210m to settle charity-kickback claims
United Therapeutics (NSDQ:UTHR) has agreed to pay $210 million to squash claims that it used a charity to illegally cover Medicare patients’ out-of-pocket costs in an attempt to boost sales. Drug...
View ArticleClik here to view.
Report: Drugmakers may have ducked $1.3B in Medicaid rebates
Without calling out any drug companies by name, the U.S. Dept. of Health and Human Services’ Office of Inspector General revealed this week that 10 potentially misclassified drugs may have resulted in...
View ArticleClik here to view.
AstraZeneca wins FDA nod to remove boxed warning from asthma drug label
After reviewing results from trials involving more than 41,000 asthma patients, the FDA has agreed to remove the boxed warning of serious asthma-related outcomes for AstraZeneca‘s (NYSE:AZN) Symbicort...
View Article